A recent article on Pharmacy Times outlines some of the risks and rewards of fast-tracking drug evaluations in the midst of a pandemic.
One key risk, according to the article, is the lack of data surrounding COVID-19.
“As we continue to navigate the world’s new normal, it is important to think critically and ask the difficult questions,” the author, BHE’s Matthew Sussman, writes. “Although there may ultimately be no universal correct answer, there is much to be learned from questions posed and research considered.”
To read the full article on Pharmacy Times, click here.